Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Tigers starter Olson leaves game against Royals after being struck by line drive
Mother, 24, outraged after learning shopping centre bathroom with baby changing facilities has CCTV
Archbishop of Canterbury says Kate Middleton conspiracy theories are nothing more than 'old
Thomas Kingston dies aged 45: How the royal family will form a tight circle of support around much
U.S. dispatches general in charge of the Middle East to F
New York's high court upholds requiring insurance to cover medically necessary abortions
Princess Beatrice and Edoardo Mapelli Mozzi are all smiles as they join his mother